首例托法替布治疗免疫检查点抑制剂相关性关节炎。
First use of tofacitinib to treat an immune checkpoint inhibitor-induced arthritis.
机构信息
EULAR Centre for Arthritis and Rheumatic Disease, St. Vincent's University Hospital, Dublin, Ireland.
Molecular Rheumatology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.
出版信息
BMJ Case Rep. 2021 Feb 4;14(2):e238851. doi: 10.1136/bcr-2020-238851.
Abstract
Immune checkpoint inhibitors have revolutionised cancer treatment; however, immune-related adverse events do occur, with up to 7% developing inflammatory arthritis. Common rheumatoid arthritis therapies such as methotrexate, prednisolone and biologics have been used to treat this arthritis in small, uncontrolled case series with varying success. In this case of personalised medicine, we report the first use of tofacitinib, a small molecular inhibitor of the Janus kinase-signal transducer and activator of transcription pathway, to treat checkpoint inhibitor-related inflammatory arthritis. This resulted in a rapid clinical response and complete, sustained remission of the arthritis with associated marked reduction in synovial molecular and cellular immune response.
摘要
免疫检查点抑制剂彻底改变了癌症治疗；然而，免疫相关不良反应确实会发生，多达 7%的患者会发生炎症性关节炎。在一些小型、非对照的病例系列研究中，曾使用甲氨蝶呤、泼尼松龙和生物制剂等常见的类风湿关节炎治疗药物来治疗此类关节炎，但疗效不一。在这种个体化医学的情况下，我们报告了使用托法替布（一种 Janus 激酶信号转导和转录激活因子通路的小分子抑制剂）治疗检查点抑制剂相关炎症性关节炎的首例病例。这导致了快速的临床反应和关节炎的完全、持续缓解，同时也显著降低了滑膜分子和细胞免疫反应。
相似文献
1
First use of tofacitinib to treat an immune checkpoint inhibitor-induced arthritis.首例托法替布治疗免疫检查点抑制剂相关性关节炎。
BMJ Case Rep. 2021 Feb 4;14(2):e238851. doi: 10.1136/bcr-2020-238851.
2
The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.JAK抑制剂托法替布可抑制类风湿关节炎中滑膜的JAK1-STAT信号传导。
Ann Rheum Dis. 2015 Jun;74(6):1311-6. doi: 10.1136/annrheumdis-2014-206028. Epub 2014 Nov 14.
3
Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study.托法替布治疗类风湿关节炎的疗效和安全性：一项队列研究。
Arthritis Res Ther. 2018 Mar 23;20(1):60. doi: 10.1186/s13075-018-1539-6.
4
Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside.类风湿关节炎JAK抑制剂的最新进展与展望：从实验台到临床应用
J Biochem. 2015 Sep;158(3):173-9. doi: 10.1093/jb/mvv069. Epub 2015 Jul 7.
5
Osteoimmunology in rheumatoid and psoriatic arthritis: potential effects of tofacitinib on bone involvement.类风湿关节炎和银屑病关节炎中的骨免疫学：托法替布对骨骼受累的潜在影响。
Clin Rheumatol. 2020 Mar;39(3):727-736. doi: 10.1007/s10067-020-04930-x. Epub 2020 Jan 22.
6
Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.托法替布：首个用于治疗类风湿关节炎的 Janus 激酶（JAK）抑制剂。
Ann Pharmacother. 2013 Nov;47(11):1524-31. doi: 10.1177/1060028013512790.
7
Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea.托法替布治疗韩国中重度类风湿关节炎的成本效益
Clin Ther. 2015 Aug;37(8):1662-76.e2. doi: 10.1016/j.clinthera.2015.07.001. Epub 2015 Aug 1.
8
Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for rheumatoid arthritis.Janus 激酶抑制剂托法替布治疗类风湿关节炎过程中对循环血清淀粉样蛋白 A 和白细胞介素 6 的影响。
Clin Exp Immunol. 2014 Feb;175(2):208-14. doi: 10.1111/cei.12234.
9
Tofacitinib in the Treatment of Rheumatoid Arthritis and Chronic Plaque Psoriasis.托法替布治疗类风湿关节炎和慢性斑块状银屑病。
Skin Therapy Lett. 2017 Mar;22(2):1-7.
10
Malignancy and Janus Kinase Inhibition.恶性肿瘤与Janus激酶抑制
Rheum Dis Clin North Am. 2017 Feb;43(1):79-93. doi: 10.1016/j.rdc.2016.09.008.
引用本文的文献
1
Use of Upadacitinib to Treat a Severe Flare-Up of Rheumatoid Arthritis During Anti-PD-1 Immune Checkpoint Inhibitor Therapy for Stage IV Squamous Cell Carcinoma of the Lung.在使用抗程序性死亡蛋白1（PD-1）免疫检查点抑制剂治疗IV期肺鳞状细胞癌期间，使用乌帕替尼治疗类风湿关节炎的严重发作。
J Clin Med. 2024 Oct 20;13(20):6257. doi: 10.3390/jcm13206257.
2
Checkpoint Inhibitor-Induced Autoimmune Diabetes: An Autoinflammatory Disease.检查点抑制剂诱导的自身免疫性糖尿病：一种自身炎症性疾病。
Cold Spring Harb Perspect Med. 2025 Apr 1;15(4):a041603. doi: 10.1101/cshperspect.a041603.
3
Rheumatic adverse events of immune checkpoint inhibitors in cancer immunotherapy.癌症免疫治疗中免疫检查点抑制剂的风湿性不良事件。
Expert Rev Clin Immunol. 2024 Aug;20(8):873-893. doi: 10.1080/1744666X.2024.2323966. Epub 2024 Mar 19.
4
Rheumatic complications of checkpoint inhibitors: Lessons from autoimmunity.检查点抑制剂的风湿性并发症：自身免疫中的教训。
Immunol Rev. 2023 Sep;318(1):51-60. doi: 10.1111/imr.13242. Epub 2023 Jul 12.
5
Immune-related pulmonary toxicities of checkpoint inhibitors in non-small cell lung cancer: Diagnosis, mechanism, and treatment strategies.免疫检查点抑制剂相关的非小细胞肺癌肺部毒性：诊断、机制和治疗策略。
Front Immunol. 2023 Apr 4;14:1138483. doi: 10.3389/fimmu.2023.1138483. eCollection 2023.
6
Distinct immune-effector and metabolic profile of CD8 T cells in patients with autoimmune polyarthritis induced by therapy with immune checkpoint inhibitors.免疫检查点抑制剂治疗诱导的自身免疫性多关节炎患者中CD8 T细胞独特的免疫效应和代谢特征
Ann Rheum Dis. 2022 Nov 10;81(12):1730-1741. doi: 10.1136/ard-2022-222451.
7
Monitoring and Management of the Patient with Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis: Current Perspectives.免疫检查点抑制剂诱导的炎性关节炎患者的监测与管理：当前观点
J Inflamm Res. 2022 May 25;15:3105-3118. doi: 10.2147/JIR.S282600. eCollection 2022.
8
Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition.免疫检查点抑制相关免疫相关不良反应的潜在治疗方法：从单克隆抗体到激酶抑制。
J Immunother Cancer. 2022 Jan;10(1). doi: 10.1136/jitc-2021-003551.
9
Facts and Hopes in Prediction, Diagnosis, and Treatment of Immune-Related Adverse Events.预测、诊断和治疗免疫相关不良事件的事实和希望。
Clin Cancer Res. 2022 Apr 1;28(7):1250-1257. doi: 10.1158/1078-0432.CCR-21-1240.
10
A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?JAK 抑制剂十年：我们学到了什么，未来又会怎样？
Arthritis Rheumatol. 2021 Dec;73(12):2166-2178. doi: 10.1002/art.41906. Epub 2021 Nov 2.
本文引用的文献
1
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.EULAR 针对癌症免疫治疗中使用检查点抑制剂引起的风湿免疫相关不良事件的诊断和管理的考虑要点。
Ann Rheum Dis. 2021 Jan;80(1):36-48. doi: 10.1136/annrheumdis-2020-217139. Epub 2020 Apr 23.
2
Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation.免疫检查点抑制剂诱导的炎症性关节炎在免疫治疗停止后仍然存在。
Ann Rheum Dis. 2020 Mar;79(3):332-338. doi: 10.1136/annrheumdis-2019-216109. Epub 2019 Sep 20.
3
Association of synovial tissue polyfunctional T-cells with DAPSA in psoriatic arthritis.滑膜组织多功能 T 细胞与银屑病关节炎中 DAPSA 的关联。
Ann Rheum Dis. 2019 Mar;78(3):350-354. doi: 10.1136/annrheumdis-2018-214138. Epub 2019 Jan 9.
4
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.免疫检查点抑制剂相关致命性毒性作用：系统评价和荟萃分析。
JAMA Oncol. 2018 Dec 1;4(12):1721-1728. doi: 10.1001/jamaoncol.2018.3923.
5
JAK/STAT Blockade Alters Synovial Bioenergetics, Mitochondrial Function, and Proinflammatory Mediators in Rheumatoid Arthritis.JAK/STAT 阻断剂改变类风湿关节炎滑膜生物能量学、线粒体功能和促炎介质。
Arthritis Rheumatol. 2018 Dec;70(12):1959-1970. doi: 10.1002/art.40569. Epub 2018 Oct 27.
6
Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression.免疫检查点抑制剂PD-1通路在类风湿性关节炎疾病进展的各个阶段滑膜中下调。
PLoS One. 2018 Feb 28;13(2):e0192704. doi: 10.1371/journal.pone.0192704. eCollection 2018.
7
Augmented Th17 Differentiation Leads to Cutaneous and Synovio-Entheseal Inflammation in a Novel Model of Psoriatic Arthritis.增强的 Th17 分化导致银屑病关节炎新型模型中的皮肤和滑膜-腱膜炎症。
Arthritis Rheumatol. 2018 Jun;70(6):855-867. doi: 10.1002/art.40447. Epub 2018 Apr 18.
8
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.与免疫检查点阻断相关的免疫相关不良事件。
N Engl J Med. 2018 Jan 11;378(2):158-168. doi: 10.1056/NEJMra1703481.
9
Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series.托珠单抗成功治疗免疫检查点抑制剂相关关节炎：病例系列。
Ann Rheum Dis. 2017 Dec;76(12):2061-2064. doi: 10.1136/annrheumdis-2017-211560. Epub 2017 Aug 22.
10
Ex-Th17 (Nonclassical Th1) Cells Are Functionally Distinct from Classical Th1 and Th17 Cells and Are Not Constrained by Regulatory T Cells.前Th17（非经典Th1）细胞在功能上与经典Th1和Th17细胞不同，且不受调节性T细胞的限制。
J Immunol. 2017 Mar 15;198(6):2249-2259. doi: 10.4049/jimmunol.1600737. Epub 2017 Feb 6.
Zotero 插件